

SUMMARY OF CHANGES
Amendment #4: November 29, 2010
(Broadcast: December 16, 2010)

RTOG 0825/ACRIN 6686, Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

Study Chair: Mark R. Gilbert, MD; 713-792-4008; mrgilbert@mdanderson.org

RTOG 0825/ACRIN 6686 was amended as follows:

RTOG 0825

As mandated by CTEP, beginning December 31, 2010, this study will utilize CTCAE version 4.0 for AdEERS reporting of adverse events. Related changes were made to **Section 7.10, 1st paragraph**.

NOTE: All AE reporting on the study case report forms will continue to use CTCAE version 3.0.

ACRIN 6686

Similarly, ACRIN has updated the previous language referencing “most recent version” of the CTCAE to specify version 4.0. Revisions are included in **Appendix XV, Section 8.3, 1st sentence**, and in **Section 8.6, in the footnote below the “Type of Report” table**.

RTOG 0825/ACRIN 6686

A document version history was added to the **Cover Page** per current RTOG standard.